Loomis Sayles & Co. L P trimmed its stake in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 1.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 573,212 shares of the specialty pharmaceutical company’s stock after selling 6,460 shares during the quarter. Loomis Sayles & Co. L P owned approximately 1.10% of Supernus Pharmaceuticals worth $28,861,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Glenmede Trust Co. NA lifted its stake in Supernus Pharmaceuticals by 3.2% in the second quarter. Glenmede Trust Co. NA now owns 652,806 shares of the specialty pharmaceutical company’s stock valued at $39,070,000 after buying an additional 20,012 shares during the last quarter. Icon Advisers Inc. Co. bought a new stake in Supernus Pharmaceuticals in the third quarter valued at $3,877,000. Oppenheimer Asset Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 9.2% during the third quarter. Oppenheimer Asset Management Inc. now owns 14,813 shares of the specialty pharmaceutical company’s stock valued at $746,000 after purchasing an additional 1,251 shares during the period. Cynosure Advisors LLC increased its holdings in shares of Supernus Pharmaceuticals by 55.0% during the second quarter. Cynosure Advisors LLC now owns 8,260 shares of the specialty pharmaceutical company’s stock valued at $494,000 after purchasing an additional 2,930 shares during the period. Finally, SevenBridge Financial Group LLC acquired a new position in shares of Supernus Pharmaceuticals during the second quarter valued at $113,000. Institutional investors own 97.52% of the company’s stock.
A number of research analysts have recently commented on the company. Zacks Investment Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, November 8th. Piper Jaffray Companies reissued a “hold” rating and set a $44.00 price target on shares of Supernus Pharmaceuticals in a report on Thursday, August 9th. BidaskClub lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 7th. ValuEngine raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. Finally, Jefferies Financial Group raised their price target on Supernus Pharmaceuticals from $55.00 to $58.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Supernus Pharmaceuticals has an average rating of “Buy” and a consensus target price of $56.89.
Shares of SUPN opened at $46.01 on Thursday. The firm has a market cap of $2.40 billion, a PE ratio of 36.52, a price-to-earnings-growth ratio of 1.45 and a beta of 0.93. The company has a current ratio of 2.82, a quick ratio of 2.65 and a debt-to-equity ratio of 0.77. Supernus Pharmaceuticals Inc has a one year low of $34.90 and a one year high of $61.25.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to analyst estimates of $100.75 million. Supernus Pharmaceuticals had a return on equity of 30.30% and a net margin of 25.89%. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period last year, the company earned $0.29 earnings per share. Sell-side analysts anticipate that Supernus Pharmaceuticals Inc will post 1.87 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/12/06/loomis-sayles-co-l-p-sells-6460-shares-of-supernus-pharmaceuticals-inc-supn.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.
Read More: What strategies should day traders use to execute a trade?
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.